2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
- 28 February 2009
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 136 (2), 486-495
- https://doi.org/10.1053/j.gastro.2008.10.026
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatology International, 2008
- Dynamics of lamivudine‐resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapyJournal of Medical Virology, 2008
- Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for managementJournal of Hepatology, 2007
- Rescue therapy for lamivudine-resistant chronic hepatitis B: When and how?Journal of Hepatology, 2007
- Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 YearsGastroenterology, 2006
- 388 Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicityJournal of Hepatology, 2006
- 514 HBV resistance determination from the telbivudine globe registration trialJournal of Hepatology, 2006
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen—Positive Chronic Hepatitis BGastroenterology, 2005
- Quantitation of Hepatitis B Viremia and Emergence of YMDD Variants in Patients with Chronic Hepatitis B Treated with LamivudineThe Journal of Infectious Diseases, 1999